AstraZeneca plc (AZN) Given “Buy” Rating at Berenberg Bank
Berenberg Bank reiterated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note issued to investors on Wednesday. The brokerage currently has a GBX 5,800 ($76.54) price target on the biopharmaceutical company’s stock.
Several other research analysts have also recently commented on AZN. J P Morgan Chase & Co reiterated a neutral rating on shares of AstraZeneca plc in a report on Wednesday. HSBC Holdings plc boosted their price target on shares of AstraZeneca plc from GBX 4,150 ($54.76) to GBX 4,340 ($57.27) and gave the stock a reduce rating in a report on Wednesday. Liberum Capital reiterated a hold rating and set a GBX 5,000 ($65.98) price target on shares of AstraZeneca plc in a report on Wednesday. Kepler Capital Markets boosted their price target on shares of AstraZeneca plc from GBX 5,200 ($68.62) to GBX 5,250 ($69.28) and gave the stock a buy rating in a report on Wednesday. Finally, Deutsche Bank AG reiterated a buy rating and set a GBX 5,600 ($73.90) price target on shares of AstraZeneca plc in a report on Wednesday. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. AstraZeneca plc currently has a consensus rating of Hold and an average price target of GBX 5,183.55 ($68.40).
WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.watchlistnews.com/astrazeneca-plc-azn-given-buy-rating-at-berenberg-bank/1674145.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.